Panel of neuroscience experts lays out the complications with using Biogen's new Alzheimer's drug

Panel of neuroscience experts lays out the complications with using Biogen's new Alzheimer's drug

Source: 
Endpoints
snippet: 

Treatment of early Alzheimer’s patients with Biogen’s new drug Aduhelm should closely resemble how the drug was studied in its pivotal clinical trials, according to new recommendations from a panel of neuroscience experts led by UNLV’s Jeffrey Cummings.